Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study

Neurology and Therapy

Volumn 4, Issue 2, 2015, Pages 137-146

  Theodore Phillips, J ^a   Erwin, April A ^b   Agrella, Stephanie ^c   Kremenchutzky, Marcelo ^d   Kramer, John F ^e   Darkes, Malcolm J M ^f   Kendter, Jonathan ^g   Abourjaily, Heather ^g   Rana, Jitesh ^g   Fox, Robert J ^h  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b NeuroMedical Center Clinic   (United States)

^c Multiple Sclerosis Clinic of Central Texas   (United States)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e Center for Neurological Disorders   (United States)

^f Excel Scientific Solutions   (United Kingdom)

^g BIOGEN   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Delayed release dimethyl fumarate; Delphi technique; Disease management; Health care surveys; Multiple sclerosis

Indexed keywords

ANTACID AGENT; ATROPINE PLUS DIPHENOXYLATE; BISMUTH SALICYLATE; DICYCLOVERINE; DIMENHYDRINATE; FUMARIC ACID DIMETHYL ESTER; HISTAMINE H2 RECEPTOR ANTAGONIST; LOPERAMIDE; METOCLOPRAMIDE; ONDANSETRON; PROCHLORPERAZINE; PROMETHAZINE; PROTON PUMP INHIBITOR; SIMETHICONE; SUCRALFATE;

ABDOMINAL PAIN; ARTICLE; CONSENSUS; CONSENSUS DEVELOPMENT; DELAYED RELEASE FORMULATION; DELPHI STUDY; DIARRHEA; DISEASE MANAGEMENT; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HEALTH CARE SURVEY; HUMAN; IATROGENIC DISEASE; MULTIPLE SCLEROSIS; NAUSEA; NURSE PRACTITIONER; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; VOMITING;

EID: 84977083318     PISSN: 21938253     EISSN: 21936536     Source Type: Journal    
DOI: 10.1007/s40120-015-0037-x     Document Type: Article

References (12)

1. Tecfidera (prescribing information). http://www.tecfidera.com/pdfs/full-prescribing-info.pdf. Accessed 27 April 2015.
2. European Medicines Agency. Tecfidera summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002601/WC500162069.pdf. Accessed 27 April 2015.
3. Gold R, Kappos L, Arnold DL, DEFINE Study Investigators, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–107.
4. Fox RJ, Miller DH, Phillips JT, CONFIRM Study Investigators, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–97.
5. Viglietta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2:103–18.
6. Meltzer L, Selmaj K, Gold R, et al. Gastrointestinal tolerability events in relapsing-remitting multiple sclerosis patients treated with BG-12 (dimethyl fumarate) in DEFINE and CONFIRM. Neurology. 2013;80(meeting abstracts 1):P01.164.
7. Devonshire V, Lapierre Y, Macdonell R, et al. GAP Study Group. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18:69–77.
8. Hsu C-C, Sandford B. The Delphi technique: making sense of consensus. Pract Assess Res Eval [serial online] 2007;12:1–8. http://pareonline.net/getvn.asp?v=12&n=10. Accessed 27 April 2015.
9. Delbecq A, Van de Ven AH, Gustafson DH. The Delphi technique. In: Delbecq A, Van de Ven AH, Gustafson DH. Group techniques for program planning: a guide to nominal group and Delphi processes. Glenview, IL: Scott, Forseman, and Company; 1975.
10. Brandes DW, Callender T, Lathi E, O’Leary S. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin. 2009;25:77–92.
11. Phillips JT, Hutchinson M, Fox R, Gold R, Havrdova E. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel. Mult Scler Relat Disord. 2014;3:513–9.
12. Dalkey NC, Brown BB, Cochran S. The Delphi method. Santa Monica: Rand Corporation; 1969.